Back to search
FDAFDA · Food and drugs·Recall number D-1081-2019

Losartan 50mg Tablet, 30 count each blister card.

Published April 17, 2019 · Recall initiated: March 14, 2019

Summary

FDA records drug Class II recall D-1081-2019, published April 17, 2019 and initiated March 14, 2019. Recalling firm: RemedyRepack Inc.; Status: Terminated; Reported quantity: 33 blister cards of 30 = 990 tablets; Lot: 70518-0588-01, Lot #: J0328416-101518, Exp. Date: 10/2019. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations; Detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) - N-Methylnitrosobutyric acid (NMBA).

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
RemedyRepack Inc.
Distributor
Product was distributed to one sole customer, Miami, FL.
Lot
70518-0588-01, Lot #: J0328416-101518, Exp. Date: 10/2019
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Losartan 50mg Tablet, 30 count each blister card. recalled?

Yes. FDA published recall D-1081-2019 on April 17, 2019. Reported hazard: CGMP Deviations; Detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) - N-Methylnitrosobutyric acid (NMBA).

What should I do if I have this product?

Voluntary: Firm initiated · Letter